Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN G PROCAINE versus PENTIDS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN G PROCAINE versus PENTIDS 250.
PENICILLIN G PROCAINE vs PENTIDS '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Penicillin G binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and cell wall synthesis, leading to bacterial lysis.
1.2 million to 2.4 million units intramuscularly once daily for most infections (e.g., uncomplicated pneumonia); for neurosyphilis, 2.4 million units intramuscularly once daily plus probenecid 500 mg orally four times daily for 10-14 days. Administer deep IM injection, not IV.
250 mg orally every 8 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 0.5-1 hour in patients with normal renal function. Clinically, the prolonged absorption from the intramuscular depot results in sustained serum concentrations, with effective levels lasting 12-24 hours.
0.5-1 hour (prolonged in renal impairment; requires dose adjustment when CrCl <30 mL/min)
Primarily renal excretion via tubular secretion and glomerular filtration. Approximately 60-90% of a dose is excreted unchanged in urine within 24 hours. Biliary/fecal elimination is minor (<10%).
Primarily renal (60-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (10-30%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic